Maria-Louisa Izamis1, Sinem Perk2, Candice Calhoun3, Korkut Uygun4, Martin L Yarmush5, François Berthiaume6. 1. Center for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Harvard Medical School, and Shriners Burns Hospital, 51 Blossom Street, Boston, MA 02114, United States. Electronic address: mizamis@mgh.harvard.edu. 2. Center for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Harvard Medical School, and Shriners Burns Hospital, 51 Blossom Street, Boston, MA 02114, United States. Electronic address: perksin@gmail.com. 3. Center for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Harvard Medical School, and Shriners Burns Hospital, 51 Blossom Street, Boston, MA 02114, United States. Electronic address: Calhoun.ck@gmail.com. 4. Center for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Harvard Medical School, and Shriners Burns Hospital, 51 Blossom Street, Boston, MA 02114, United States. Electronic address: uygun.korkut@mgh.harvard.edu. 5. Center for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Harvard Medical School, and Shriners Burns Hospital, 51 Blossom Street, Boston, MA 02114, United States; Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, United States. Electronic address: ireis@sbi.org. 6. Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, United States. Electronic address: fberthia@rci.rutgers.edu.
Abstract
BACKGROUND: High-quality human hepatocytes form the basis of drug safety and efficacy tests, cell-based therapies, and bridge-to-transplantation devices. Presently the only supply of cells derives from an inadequate pool of suboptimal disqualified donor livers. Here we evaluated whether machine perfusion could ameliorate ischemic injury that many of these livers experience prior to hepatocyte isolation. METHODS: Non-heparinized female Lewis rat livers were exposed to an hour of warm ischemia (34°C) and then perfused for 3h. Five different perfusion conditions that utilized the cell isolation apparatus were investigated, namely: (1) modified Williams Medium E and (2) Lifor, both with active oxygenation (95%O(2)/5%CO(2)), as well as (3) Lifor passively oxygenated with ambient air (21%O(2)/0.04%CO(2)), all at ambient temperatures (20 ± 2°C). At hypothermic temperatures (5 ± 1°C) and under passive oxygenation were (4) University of Wisconsin solution (UW) and (5) Vasosol. Negative and positive control groups comprised livers that had ischemia (WI) and livers that did not (Fresh) prior to cell isolation, respectively. RESULTS: Fresh livers yielded 32 ± 9 million cells/g liver while an hour of ischemia reduced the cell yield to 1.6 ± 0.6 million cells/g liver. Oxygenated Williams Medium E and Lifor recovered yields of 39 ± 11 and 31 ± 2.3 million cells/g liver, respectively. The passively oxygenated groups produced 15 ± 7 (Lifor), 13 ± 7 (Vasosol), and 10 ± 6 (UW)million cells/g liver. Oxygenated Williams Medium E was most effective at sustaining pH values, avoiding the accumulation of lactate, minimizing edematous weight gain and producing bile during perfusion. CONCLUSIONS: Machine perfusion results in a dramatic increase in cell yields from livers that have had up to an hour of warm ischemia, but perfusate choice significantly impacts the extent of recovery. Oxygenated Williams Medium E at room temperature is superior to Lifor, UW and Vasosol, largely facilitated by its high oxygen content and low viscosity.
BACKGROUND: High-quality human hepatocytes form the basis of drug safety and efficacy tests, cell-based therapies, and bridge-to-transplantation devices. Presently the only supply of cells derives from an inadequate pool of suboptimal disqualified donor livers. Here we evaluated whether machine perfusion could ameliorate ischemic injury that many of these livers experience prior to hepatocyte isolation. METHODS: Non-heparinized female Lewis rat livers were exposed to an hour of warm ischemia (34°C) and then perfused for 3h. Five different perfusion conditions that utilized the cell isolation apparatus were investigated, namely: (1) modified Williams Medium E and (2) Lifor, both with active oxygenation (95%O(2)/5%CO(2)), as well as (3) Lifor passively oxygenated with ambient air (21%O(2)/0.04%CO(2)), all at ambient temperatures (20 ± 2°C). At hypothermic temperatures (5 ± 1°C) and under passive oxygenation were (4) University of Wisconsin solution (UW) and (5) Vasosol. Negative and positive control groups comprised livers that had ischemia (WI) and livers that did not (Fresh) prior to cell isolation, respectively. RESULTS: Fresh livers yielded 32 ± 9 million cells/g liver while an hour of ischemia reduced the cell yield to 1.6 ± 0.6 million cells/g liver. Oxygenated Williams Medium E and Lifor recovered yields of 39 ± 11 and 31 ± 2.3 million cells/g liver, respectively. The passively oxygenated groups produced 15 ± 7 (Lifor), 13 ± 7 (Vasosol), and 10 ± 6 (UW)million cells/g liver. Oxygenated Williams Medium E was most effective at sustaining pH values, avoiding the accumulation of lactate, minimizing edematous weight gain and producing bile during perfusion. CONCLUSIONS: Machine perfusion results in a dramatic increase in cell yields from livers that have had up to an hour of warm ischemia, but perfusate choice significantly impacts the extent of recovery. Oxygenated Williams Medium E at room temperature is superior to Lifor, UW and Vasosol, largely facilitated by its high oxygen content and low viscosity.
Authors: J Pirenne; F Van Gelder; W Coosemans; R Aerts; B Gunson; T Koshiba; I Fourneau; D Mirza; W Van Steenbergen; J Fevery; F Nevens; P McMaster Journal: Liver Transpl Date: 2001-06 Impact factor: 5.799
Authors: F Gage; D B Leeser; N K Porterfield; J C Graybill; S Gillern; J S Hawksworth; R M Jindal; N Thai; E M Falta; D K Tadaki; T S Brown; E A Elster Journal: Transplant Proc Date: 2009-11 Impact factor: 1.066
Authors: B G Bruinsma; H Yeh; S Ozer; P N Martins; A Farmer; W Wu; N Saeidi; S Op den Dries; T A Berendsen; R N Smith; J F Markmann; R J Porte; M L Yarmush; K Uygun; M-L Izamis Journal: Am J Transplant Date: 2014-04-23 Impact factor: 8.086
Authors: Achilles A Demetriou; Robert S Brown; Ronald W Busuttil; Jeffrey Fair; Brendan M McGuire; Philip Rosenthal; Jan Schulte Am Esch; Jan Lerut; Scott L Nyberg; Mauro Salizzoni; Elizabeth A Fagan; Bernard de Hemptinne; Christoph E Broelsch; Maurizio Muraca; Joan Manuel Salmeron; John M Rabkin; Herold J Metselaar; Daniel Pratt; Manuel De La Mata; Lawrence P McChesney; Gregory T Everson; Philip T Lavin; Anthony C Stevens; Zorina Pitkin; Barry A Solomon Journal: Ann Surg Date: 2004-05 Impact factor: 12.969
Authors: J V Guarrera; S D Henry; B Samstein; R Odeh-Ramadan; M Kinkhabwala; M J Goldstein; L E Ratner; J F Renz; H T Lee; R S Brown; J C Emond Journal: Am J Transplant Date: 2009-12-02 Impact factor: 8.086
Authors: David F Stowe; Amadou K S Camara; James S Heisner; Mohammed Aldakkak; David R Harder Journal: J Heart Lung Transplant Date: 2008-07-26 Impact factor: 10.247
Authors: Sinem Perk; Maria-Louisa Izamis; Herman Tolboom; Basak Uygun; Francois Berthiaume; Martin L Yarmush; Korkut Uygun Journal: PLoS One Date: 2011-12-14 Impact factor: 3.240
Authors: Basak E Uygun; Maria-Louisa Izamis; Maria Jaramillo; Yibin Chen; Gavrielle Price; Sinan Ozer; Martin L Yarmush Journal: Artif Organs Date: 2016-11-08 Impact factor: 3.094
Authors: Omar Haque; Casie A Pendexter; Stephanie E J Cronin; Siavash Raigani; Reiner J de Vries; Heidi Yeh; James F Markmann; Korkut Uygun Journal: Technology (Singap World Sci) Date: 2020-11-05
Authors: James E Squires; Kyle A Soltys; Patrick McKiernan; Robert H Squires; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez Journal: Curr Transplant Rep Date: 2017-10-14